Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based specialty pharmaceutical company Biovail has announced that the FDA has accepted the company's abbreviated new drug application for a generic formulation of 145mg and 48mg strengths of fenofibrate tablets, sold under the brand name Tricor by Abbott Laboratories.
Subscribe to our email newsletter
Tricor is a lipid-lowering agent used to treat abnormal lipid levels in the bloodstream, including cholesterol and triglycerides. The product is available in 145mg and 48mg strengths.
Bill Wells, Biovail’s CEO, said: “This represents the second successful abbreviated new drug application (ANDA) filing in the past six months. While our primary focus remains the implementation of our new strategic focus, we continue to make progress with our existing pipeline products.”